WVE - ウェ―ブ・ライフ・サイエンシズ （WAVE Life Sciences Ltd.） ウェ―ブ・ライフ・サイエンシズWVEのチャート
WVEの企業情報
| symbol | WVE |
|---|---|
| 会社名 | Wave Life Sciences Ltd （ウェ―ブ・ライフ・サイエンシズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ウェーブ・ライフ・サイエンス（WAVE Life Sciences Ltd.）は遺伝子医薬品会社である。同社は合成化学薬品開発プラットフォームを通じて遺伝的定義された疾患向けの核酸治療候補製品パイプラインを設計、開発と商業化する。同社は疾患を促進するタンパク質の発現または機能不全の変異体タンパク質の産生を機能性タンパク質の産生に変換するために遺伝的欠陥を標的とするオリゴヌクレオチドを開発する。同社は核酸治療薬stereopureを開発する。stereopureオリゴヌクレオチドは各連結部に3次元配向で配置された原子を有する分子を含む。同社はハンチントン病（HD）とデュシェンヌ型筋ジストロフィー（DMD）にある3つのプログラムと3つの追加的開発候補製品を有する。 ウェ―ブ・ライフ・サイエンシズはシンガポ―ルのバイオ医薬品企業。臨床の前段階の研究に従事し、主に核酸医薬に焦点を当て根治が難しい病気に対する治療を目指す。遺伝子治療において、難病を進行させるタンパク質の発現を減らす方法、または機能不全の変異体タンパク質を機能的なタンパク質に変える方法などを研究・開発する。 Wave Life Sciences is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company's proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. |
| 本社所在地 | 7 Straits View #12-00 Marina One East Tower 018936 SGP |
| 代表者氏名 | Gregory L. Verdine グレゴリー・L・ヴェルディネ |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | -620784 |
| 設立年月日 | 41091 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 168人 |
| url | www.wavelifesciences.com |
| nasdaq_url | https://www.nasdaq.com/symbol/wve |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -126.02700 |
| 終値（lastsale） | 42.98 |
| 時価総額（marketcap） | 1260271035.66 |
| 時価総額 | 時価総額（百万ドル） 1300.736 |
| 売上高 | 売上高（百万ドル） 8.65300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 167.179 |
| 当期純利益 | 当期純利益（百万ドル） -127.48100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Wave Life Sciences Ltd revenues increased from $1.5M to $6.3M. Net loss increased 56% to $71.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 82% to $61.7M (expense) General and administrative increase of 35% to $16.9M (expense). |
WVEのテクニカル分析
WVEのニュース
Wave Life Sciences to Present at the 2022 Jefferies Healthcare Conference 2022/05/25 12:30:00 GlobeNewswire
CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the 2022 Jefferies Healthcare Conference in New York City on Wednesday, June 8, 2022, at 3:00 p.m. ET.
Ahead Of Upcoming Data On Three Programs, Analysts Remain On Sidelines For Wave Life Sciences 2022/05/13 18:51:16 Benzinga
RBC Capital writes that Wave Life Sciences Ltd''s (NASDAQ: WVE ) Q1 earnings are largely incremental. The company reiterated that they had extended the observation period in the SAD part of the C9-study (30 mg dose has yet to plateau) and continued optimizing dose levels and frequency. A data update is expected in 2022 and first looks at Huntington''s disease (HD) and Duchenne muscular dystrophy (DMD). At a negative EV and three upcoming clinical catalysts, RBC sees potential upside, but difficult to have strong conviction given two initial clinical … Full story available on Benzinga.com
WVE stock slips as H.C. Wainwright lowers target (NASDAQ:WVE) 2022/05/13 14:18:20 Seeking Alpha
Then shares of Wave Life Sciences (WVE) are trading lower in the morning hours Friday after H.C
Wave Life Sciences Ltd. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:WVE) 2022/05/12 18:54:02 Seeking Alpha
The following slide deck was published by Wave Life Sciences Ltd.
Wave Life Sciences GAAP EPS of -$0.62 misses by $0.06, revenue of $1.75M misses by $2.11M 2022/05/12 11:32:13 Seeking Alpha
Wave Life Sciences press release (WVE): Q1 GAAP EPS of -$0.62 misses by $0.06.Revenue of $1.75M (+17400.0% Y/Y) misses by $2.11M.As of March 31, 2022, Wave had $111.7 million in…
Wave Life Sciences: Q2 Earnings Snapshot 2021/08/05 12:42:14 One News Page
SINGAPORE (AP) _ Wave Life Sciences Pte. Ltd. (WVE) on Thursday reported a loss of $38.8 million in its second quarter. On a per-share basis, the Singapore-based company said it had a loss of 78 cents. The results missed Wall Street expectations. The average estimate of five analysts
Wave Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update 2021/08/05 11:30:00 Intrado Digital Media
Dosing underway in FOCUS-C9 clinical trial of WVE-004 in C9-ALS / C9-FTD first oligonucleotide using PN backbone chemistry modifications in clinical study
Wave Life Sciences to Webcast Conference Call of Second Quarter 2021 Financial Results on August 5, 2021 2021/07/26 20:05:00 Intrado Digital Media
CAMBRIDGE, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Thursday, August 5, 2021, to discuss its second quarter 2021 financial results and provide a business update.
Dosing underway in Wave Life Sciences'' mid-stage WVE-004 study in neurodegenerative diseases 2021/07/20 12:17:33 Seeking Alpha
Wave Life Sciences presents promising preclinical data for its ADAR editing program 2021/06/03 13:58:14 BioWorld
Wave Life Sciences posts proof-of-concept data from genetic disorder study 2021/06/02 21:02:52 Seeking Alpha
Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency 2021/06/02 00:00:00 BioSpace
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the first proof-of-concept preclinical data for its ADAR (adenosine deaminases acting on RNA)-mediated RNA editing (ADAR editing) program in alpha-1 antitrypsin deficiency (AATD)
Wave Life Sciences to Present at Jefferies Virtual Healthcare Conference 2021/05/28 00:00:00 BioSpace
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to give a presentation at the Jefferies Virtual Healthcare Conference